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SUMMARY  
The post-translational modification of key residues at the carboxy-terminal domain of 
RNA polymerase II (RNAP2-CTD), coordinates transcription, splicing, and RNA 
processing by modulating its capacity to act as a landing platform for a variety of 
protein complexes. Here, we identify a new modification at the CTD, the deimination of 
arginine and its conversion to citrulline by peptidyl arginine deiminase 2 (PADI2), an 
enzyme that has been associated with several diseases including cancer. We show that 
among PADI family members, only PADI2 citrullinates R1810 (Cit1810) at repeat 31 
of the CTD.  Depletion of PADI2 or loss of R1810 result in accumulation of RNAP2 at 
transcription start sites, reduced gene expression and inhibition of cell proliferation. 
Cit1810 is needed for interaction with the P-TEFb (positive transcription elongation 
factor b) kinase complex and for its recruitment to chromatin. In this way, CTD-
Cit1810 favors RNAP2 pause release and efficient transcription in breast cancer cells.  
           150 words 
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INTRODUCTION 
 
In mammals, the RNA polymerase II carboxy-terminal domain (RNAP2-CTD) 
comprises 52 heptapeptide repeats, the first half of which (1-27) exhibit the consensus 
repeat sequence Y1S2P3T4S5P6S7, whereas the second half (28-52) contains deviations 
from this consensus (Buratowski et al., 2009; Corden et al., 2013). Post-translational 
modification of the key residues at RNAP2-CTD dictate recruitment of protein 
complexes, that influence transcription elongation and the processing of the nascent 
transcripts (Jeronimo et al., 2016; Saldi et al., 2016; Harlen et al., 2017). The CTD is 
evolutionary conserved and dynamic phosphorylation of Y1, S2, T4, S5, and S7 mediates 
selective recruitment of protein complexes that modulate various phases of transcription 
(Eick et al., 2013; Zaborowska et al., 2016; Shah et al., 2018). Systematic studies using 
genetics and proteomics showed that phosphorylation of S5 and S2 is the most frequent 
modification and contributes to transcription efficiency (Schüller et al., 2016; Corden, 
2016). However, modifications in non-consensus repeats have expanded the functional 
role of the CTD code (Voss et al., 2015; Dias et al., 2015) and recent work has focused 
on methylation of arginine 1810 (R1810) at repeat 31. Its asymmetrical dimethylation 
(me2a) by the methyltransferase CARM1 (or PRMT4) inhibits the expression of small 
nuclear RNAs (snRNAs) and nucleolar RNA (snoRNA) genes in human cells (Sims et 
al., 2011). This reaction is inhibited by phosphorylation of CTD serine residues, 
suggesting that it occurs before transcription initiation. In contrast, symmetric 
dimethylation (me2s) of R1810 by PRMT5 leads to recruitment of the survival of motor 
neuron protein (SMN) and to the interaction with senataxin, that enhances 
transcriptional termination (Zhao et al., 2016). The functional significance of dynamic 
post-translational deimination of arginine residues in pathophysiological conditions 
(Slade et al., 2014; Tanikawa et al., 2018) prompted us to investigate whether this 
modification occurs at R1810 of RNAP2-CTD and its possible implication in 
transcription regulation. 
 
Citrullination is a deimination of protein-embedded arginine, which is converted 
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to the non-coded  amino acid citrulline (Van et al., 2000; Fuhrmann et al., 2015). 
Citrullination leads to a reduction in hydrogen-bond formation, affects histone-DNA 
interactions and influences the chromatin organization. Citrullination also increases the 
hydrophobicity of proteins that affect the protein folding ability and therefore the 
functional activity of proteins (Vossenaar et al., 2003; Tanikawa et al., 2018). This 
reaction is catalyzed by enzymes called peptidyl arginine deiminases (PADIs), which 
have been associated with diverse disease conditions such as thrombosis, prion disease, 
neurological disorders, autoimmune disease and cancer (Witalison et al., 2015; Gyorgy 
et al., 2006; Vossenaar et al., 2003; Baka et al., 2012). Among PADI family members, 
PADI2 is the most widely expressed isoform and is also overexpressed in breast cancer, 
where it regulates mammary carcinoma cell migration (Mohanan et al., 2012; 
Cherrington et al., 2012; Horibata et al., 2017). Citrullination of core histones has been 
related to the gene expression, DNA damage responses and pluripotency (Sharma et al., 
2012; Tanikawa et al., 2012; Christophorou et al., 2014), although the underlying 
mechanisms are largely unknown.      
RNAP2-mediated gene expression starts with binding to the gene promoters of 
basal transcription factors that recruit RNAP2 to form the transcription pre-initiation 
complex. Shortly after transcription initiation, RNAP2 pauses 30-50bp downstream of 
the transcription start sites (TSS), and requires the activation of P-TEFb (positive 
transcription elongation factor b) kinase complexes to continue with the productive 
elongation (Marshall et al., 1995; Adelman et al., 2012; Jonkers et al., 2015 ). Promoter- 
proximal pausing affects the expression of many genes but is more prominent for highly 
expressed genes in responses to developmental and environmental stimuli (Zeitlinger et 
al., 2007; Core et al., 2008; Gilchrist et al., 2010; Day et al., 2016). Recently, RNAP2 
pausing was found to inhibit transcriptional initiation, indicating that paused RNAP2 
first needs to be released in order to allow a new cycle of transcription inititation (Shao 
et al., 2017; Gressel et al., 2017). However, despite the strong evidence of RNAP2 
pausing, the nature of paused RNAP2 to allow efficient transcription still remains 
unclear. 
Here, we report the discovery that PADI2 citrullinates the R1810 (cit1810) at 
RNAP2-CTD. The absence of PADI2 mediated cit1810 widely affects transcription and 
cell proliferation in breast cancer cells. PADI2 occupancy increases with the level of 
gene transcription. Further, we found that replacing wild-type RNAP2 with the R1810A 
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mutant compromises transcription, reduces interaction with the P-TEFb complex and 
leads to accumulation of RNAP2 on the proximal promoter of PADI2 dependent genes. 
Thus, citrullination of R1810 facilitates interaction with the P-TEFb complex favoring 
RNAP2 pause release and promoting transcription of cell cycle genes and cell 
proliferation of breast cancer cells. 
 
RESULTS  
Citrullination of R1810 at RNAP2-CTD  
Two arginine residues within non-consensus repeats in human RNAP2-CTD, R1603 
and R1810, are conserved in vertebrates. Recently, R1810 within repeat 31 was found 
to be asymmetrically (Sims et al., 2011) or symmetrically (Zhao et al., 2016) 
dimethylated, leading to either reduced expression of snRNAs and snoRNA or to 
efficient transcription termination, respectively. To examine the possibility that R1810 
at RNAP2-CTD could be citrullinated in cells, we immunoprecipitated nuclear extracts 
from the luminal breast cancer cell line T47D (Truss et al., 1995) with a citrulline 
antibody followed by western blot with an antibody to RNAP2. We found two specific 
bands migrating as the non-phosphorylated (IIA) and phosphorylated (IIO) forms of the 
large subunit POLR2A of RNAP2. The IIO band reacted preferentially with α-citrulline 
compared to the IIA band of RNAP2 (Figure S1A). We raised a polyclonal antibody 
against a 13 residues peptide centered on R1810, which was replaced by citrulline 
(Figure 1A top). This antibody (α-Cit1810) was specific, as it reacted with the 
citrullinated peptide, but not with the wild-type, methylated (me2aR1810) or 
phosphorylated (S2 or S5) peptides (Figure S1B-C) and mainly recognized the 
phosphorylated form of RNAP2 in western blots of nuclear extracts from T47D cells 
(Figure 1A, Figure S1D).  
To validate that R1810 is citrullinated, we transiently transfected T47D cells 
with an α-amanitin resistant HA-tagged wild-type (WTr) RNAP2 or with a R1810Ar 
mutant of RNAP2, followed by α-amanitin treatment to deplete the endogenous RNAP2 
(Figure S1 E-G). Precipitation with anti-HA antibody followed by western blot showed 
that the WTr RNAP2, but not the R1810Ar mutant, reacts with α-Cit1810 (Figure 1B). 
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In super-resolution immunofluorescence images of T47D cells, α-Cit1810 decorated 
bright clusters overlapping with RNAP2, preferentially in its S2 or S5 phosphorylated 
forms (Figure 1C-D). Thus, R1810 is citrullinated in cells prevalently on the 
phosphorylated actively transcribing form of RNAP2.  
Citrullination of R1810 by PADI2  
In a search for the responsible enzyme, we found that T47D cells express only PADI2 
and PADI3 (Figure 2A) among family members. Depletion of PADI2 but not PADI3 
reduces R1810 citrullination (Figure 2B, Figure S2A-B). In MCF7 breast cancer cells 
that express PADI2 and PADI4 (Cuthbert et al., 2004; Sharma et al., 2012), depletion of 
PADI2 but not PADI4 reduced R1810 citrullination (Figure S2C-D). To test whether 
PADI2 acts directly on the RNAP2-CTD we incubated recombinant PADI2 with either 
a recombinant GST-N-CTD (repeat 1-25.5, including R1603) or with GST-C-CTD 
(repeat 27-52, including R1810) (Figure 2C, left panel). PADI2 citrullinates R1810 in 
the C-CTD much more efficiently than R1603 in N-CTD (Figure 2C, right panel). 
Thus, PADI2 is the enzyme responsible for citrullination of R1810 in breast cancer 
cells. 
The affinity of PADI2 for the unmodified R1810 peptide measured by 
microscale thermophoresis (Jerabek et al., 2011) is Kd=220±54.5 nM, whereas peptides 
phosphorylated at S2 or S5 were not bound (Figure 2D), suggesting that the observed 
S2/S5 phosphorylation in R1810 citrullinated CTD most probably occur outside of 
repeats 31 and 32. In co-immunoprecipitation experiments using T47D and MCF7 cells 
extracts, PADI2 but neither PADI3 or nor PADI4 interacted with RNAP2 (Figure S2E-
F). Similarly, an antibody against PADI2 precipitated Cit1810-RNAP2, along with 
S5P- and S2P-RNAP2 (Figure 2E, Figure S2G). Monoclonal antibodies against 
RNAP2 phosphorylated at S2 and S5 (see methods) precipitated Cit1810 RNAP2 as 
well as PADI2 but not PADI3 (Figure 2F). In T47D nuclear extracts fractionated using 
size exclusion chromatography PADI2 eluted along with phosphorylated RNAP2 in the 
high molecular weight fractions, whereas PADI3 eluted in lower molecular weight 
range (Figure S2H). Finally, triple labeling immunofluorescence microscopy showed 
that PADI2 co-localizes with Cit1810-RNAP2 and with S2P-RNAP2 (Figure S2I). 
These observations support the association of PADI2 with Cit1810-RNAP2 that is 
engaged in transcription.  
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Citrullination of R1810 regulates transcription and cell proliferation  
 
We next performed mRNA sequencing in control and PADI2 depleted T47D cells 
(Figure S3A). Strikingly, in global differential expression (DEseq) analysis PADI2 
knockdown affected the expression of over 4,000 genes; down regulated (2,186) and up 
regulated (2,141) (Figure 3A, Figure S3B). Gene ontology analysis of the down-
regulated genes revealed enrichment in RNAP2-mediated transcription and cell 
proliferation (Figure S3C and Table S1). Reduced expression was validated by RT-
qPCR for several genes including SERPINA6, c-MYC, and HMGN1 genes, while 
control genes GSTT2 and LRRC39 were not affected (Figure 3B, Figure S3D). 
Depletion of CARM1 or PRMT5, which catalyze dimethylation of R1810 (Sim et al., 
2011; Zhao et al., 2016), did not affect the expression of PADI2-dependent genes 
(Figure S3E-F).  
 
To explore the direct effect of PADI2 on nascent transcription, we performed 
chromatin-associated RNA sequencing (ChrRNA-seq, Nojima et al., 2016) in control 
and PADI2 depleted cells. We found that ~2,000 transcripts were significantly affected 
by the PADI2 knockdown, and the majority of them were down regulated (1,884, 
Figure 3C-D, Figure S3G). ChrRNA-seq changes were validated on PADI2-dependent 
genes by RT-qPCR (Figure 3E). We conclude that PADI2 is required for efficient 
transcription and that up regulation of mRNAs upon PADI2 depletion may be a 
consequence of down-regulation of transcription relevant genes, although we cannot 
exclude citrullination of other PADI2 substrates. To support this conclusion, we 
performed mRNA sequencing in T47D cells expressing only the α-amanitin resistant 
HA-tagged WTr or the R1810Ar mutant form of RNAP2. We found 1,392 down-
regulated genes in cells expressing R1810Ar mutant RNAP2, of which 939 (67.4%) 
were also dependent on PADI2. We confirmed this finding by RT-qPCR of a PADI2-
dependent SERPINA6, c-MYC, and HMGN1 and control genes GSTT2 and LRRC39 
(Figure 3F). Thus, PADI2 and R1810 are required for efficient transcription.  
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Since many PADI2 and R1810-dependent genes are related to cell proliferation, 
we monitored T47D cell proliferation after PADI2 depletion (siPADI2), inhibition with 
Cl-amidine, or in cells expressing only the R1810Ar mutant of RNAP2. In all cases, we 
found a significant reduction of cell proliferation (Figure 3G). PADI2-depleted cells 
were arrested at the G1 phase of the cell cycle (Figure S3H), as expected given the 
down regulation of genes critical for G1 phase progression including CCND1, PLK1 in 
presence of R1810Ar mutant as compared to WTr RNAP2 or PADI2 depletion (Figure 
3H, Table S2, Figure S3I-K).  
 
PADI2 is enriched on active genes  
 
ChIP-seq of PADI2 in T47D cells showed that 60% of chromatin-bound PADI2 was 
localized over protein-coding gene sequences, within 3kb upstream of the TSS 
(transcription start site) and 3kb downstream of the TTS (transcription termination site) 
(q value ≤0.005) (Figure 4A, left panel)). The highest enrichment (2.5-fold) was found 
in the coding exons, followed by the 3kb region downstream of the TTS (1.6-fold) 
(Figure 4A, Right panel)). Overall, PADI2 occupancy overlapped with RNAP2 binding 
measured by ChIP-seq (Figure 4B). To explore whether PADI2 binding is related to 
transcription, we separated genes in 4 quartiles according to their transcription level: 
high (100-95%), medium (95%-50%), low (last 50%) and silent (non-significant 
expression) (Baranello et al., 2016). We found that RNAP2 and PADI2 occupancy 
increased in parallel with the gene expression levels (Figure 4C, Figure S4A), 
supporting a role of PADI2 in transcription.   
 
To verify the specificity of the PADI2 occupancy, we performed PADI2 ChIP-
qPCR in control (siCTRL) and PADI2 knockdown (siPADI2) over high (SERPINA6, c-
MYC) and low expressed (GSTT2) genes and found that PADI2 depletion drastically 
decreased the levels (Figure S4B). PADI2 occupancy was significantly higher on genes 
down regulated by PADI2 depletion compared to those non-regulated (Figure S4C). 
Finally, RNAP2-ChIP followed by PADI2 re-ChIP revealed the association of RNAP2 
and PADI2 at regulatory regions and gene bodies of the highly transcribed SERPINA6, 
c-MYC genes, but not in the low expressed GSTT2 gene (Figure S4D). Thus, PADI2 
seemed to be part of the transcription machinery in highly expressed genes.  
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Citrullination of R1810 controls RNAP2 pausing    
 
Next, we analyzed RNAP2 occupancy by ChIP-qPCR in T47D cells prior and after 
PADI2 depletion. We observed accumulation of RNAP2 around the TSS of the highly 
expressed SERPINA6, c-MYC, HMGN1 genes (Figure S5A, Figure S5B right panel). 
This effect is also dependent on R1810, as it is observed in T47D cells expressing only 
the α-amanitin resistant HA-tagged R1810Ar mutant form of RNAP2 in comparison 
with cells expressing only the WTr RNAP2 (Figure 5A, Figure S5B left panel), 
suggesting absence of PADI2 mediated citrullination of R1810 leads to RNAP2 
pausing.  In T47D cells expressing only the R1810A mutant compared to cells 
expressing the WTr RNAP2, ChIP-seq experiments showed remarkably high 
accumulation of RNAP2 at proximal promoters (Figure 5B) and a corresponding 
change in the pausing index that correlated with the gene expression levels (Figure 5C). 
Previously, Raji cells expressing R1810A also showed paused RNAP2 at proximal 
promoter for the 5% most highly expressed genes (Zhao et al., 2016). 
 
Focusing on PADI2-dependent genes (n=2186), we found a pronounced 
accumulation of RNAP2 around the TSS with a significantly increased pausing index in 
presence of R1810A mutant as compared to wild-type form of RNAP2 (Figure 5D-F).  
Similarly, genes down regulated in the presence of the R1810Ar RNAP2 mutant 
(n=939) also showed significantly higher pausing index as compared to cells expressing 
WTr RNAP2 (Figure S5D). Thus, PADI2 depletion or absence of R1810 lead to 
RNAP2 accumulation on the promoters of highly expressed genes and to reduced level 
of S2P and S5P forms of RNAP2 (Figure S5C). We also found that genes up regulated 
upon depleting PADI2 or upon expressing the R1810Ar mutant RNAP2 exhibited lower 
pausing index (Figure S5E-F), suggesting that they do not need to overcome RNAP2 
pausing to maintain their expression. In summary, we found that PADI2 citrullination of 
CTD R1810 is important for RNAP2 promoter pause release.  
 
 
Cit1810 at RNAP2-CTD recognized by P-TEFb 
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Citrullination is known to modulate functional protein-protein interactions (Tanikawa et 
al., 2018; Tanikawa et al., 2012; Vossenaar et al., 2003). We wondered whether the 
Cit1810 influences the interaction of RNAP2 with the components of P-TEFb complex 
CDK9 and CCNTI (Ccylin T1), which are required for RNAP2 pause release and 
productive elongation (Jonkers et al. 2015; Gressel et al., 2017). Immunoprecipitation of 
T47D cells extracts with a PADI2 antibody, precipitated CDK9 and CCNT1 (Figure 
6A, left panel) and conversely a CDK9 antibody pulled down PADI2 (Figure 6A, right 
panel), indicating that PADI2 associates with the P-TEFb complex. 
Immunoprecipitation of extracts from PADI2 depleted cells (siPADI2) showed strong 
reduction in RNAP2 interaction with CDK9 and CCNT1 compared to control cells 
(siCTRL) (Figure 6B). In T47D or Raji cells expressing only the α-amanitin resistant 
HA-tagged WTr RNAP2, CDK9 and CCNT1 were also immunoprecipitated with HA-
tag antibody, and the interaction was significantly reduced in cells expressing the 
R1810Ar mutant RNAP2 (Figure 6C-D). Thus, PADI2 and R1810 are required for the 
association of RNAP2 with the CDK9-CCNT1 complex. Next, we performed peptide 
pull-down assays with T47D nuclear extracts using biotinylated wild type (R1810) and 
cit1810 RNAP2-CTD peptides (Figure 6E, upper panel). The cit1810 peptide pulls 
down the CDK9-CCNT1 complex much more efficiently than the wild type peptide 
(R1810) (Figure 6E, lower panel), confirming that PADI2 mediated cit1810 is required 
to facilitate cooperation of RNAP2 with CDK9-CCNT1 complex.  
 
To explore whether R1810 is important for CDK9 recruitment to the promoter 
region of genes, we performed ChIP-seq with CDK9-antibody in T47D cells expressing 
only the α-amanitin resistant HA-tagged R1810Ar or the WTr RNAP2. We found that 
CDK9 occupancy around the TSS decreased remarkably in the presence of R1810A 
mutant compared to wild-type form of RNAP2, particularly in highly expressed genes 
(Figure 6F), suggesting that the integrity of the R1810 is required for CDK9 
recruitment. When we compared PADI2 dependent and non-dependent genes we also 
found a significant decrease of CDK9 occupancy in the presence of R1810A mutant as 
compared to wild-type form of RNAP2 (Figure 6G). We validated the ChIP-seq results 
by ChIP-qPCR and confirmed that mutation of R1810 significantly decrease the 
recruitment of the CDK9 to the promoter of PADI2 target genes SERPINA6, c-MYC, 
HMGN1, but not to the low expressed genes GSST2 and LRRC39 (Figure 6H). 
Altogether, these data support the idea that PADI2 mediated citrullination of R1810 at 
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RNAP2-CTD facilitates the recruitment of P-TEFb complex that promotes RNAP2 
pause release and transcription of actively expressed genes involved in cellular 
proliferation.   
 
 
 
 
PADI2 unique residues contribute to citrullinate R1810 at RNAP2-CTD  
 
We wondered about the reason why only PADI2 but not PADI3 or nor PADI4 carries 
out citrullination of R1810 at RNAP2-CTD. To address this issue, we used the 
published structure of the PADI2 (Slade et al., 2015) to model the attachment of 
RNAP2-CTD peptide encompassing R1810 (Figure 7A), and performed a similar 
structural modeling with the amino acids of PADI3. Our analysis revealed that the 
predicted binding score energies calculated with Rosetta were significantly lower for 
PADI2 in comparison to PADI3 (Figure 7B, movie S1-S2, see method), indicating a 
higher affinity of PADI2 for the R1810 peptide.  
  
We next examined the PADI2 residues contributing most to the affinity for the 
R1810 peptide and analyzed their conservation in the PADI family. We found that non-
conserved residues in PADI2 accumulate at the rim of the catalytic domain (Figure S6), 
most likely contributing to the R1810 peptide binding. We calculated Rosetta score for 
all PADI2 interface residues (including conserved and non-conserved) and ranked them 
according to conservation among PADI family members (Figure S7A and Table S3). 
Next, we choose PADI2 specific residues R580 and L642 and also two other PADIs 
conserved residues D374 and S401 that showed comparable low binding energy of 
PADI2 toward the R1810 peptide (Figure 7A, Figure S7A), and introduced mutations 
that changed chemical properties of these four residues while maintaining the volume 
(Figure S7B). Using GST C-CTD that encompasses R1810 as a substrate for in vitro 
citrullination assays, we found that the R580E and L642T mutations drastically reduced 
citrullination activity, whereas the D374K and S401A have a non-significant effect 
(Figure 7C), confirming the specificity of PADI2 unique residues for citrullination of 
R1810.     
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DISCUSSION  
 
In this study, we identify a novel post-translational modification of the RNAP2-CTD, 
namely the citrullination by PADI2 of R1810. This modification is coupled with the 
active form of RNAP2 and regulates the transcription of highly expressed genes 
involved in cell proliferation by mediating the interaction with P-TEFb complex and 
favoring RNAP2 pause release. We detected this modification initially in T47D breast 
cancer cells with a pan-citrulline antibody and confirmed it with Cit1810 antibody 
generated using a 13-mer CTD peptide centered on Cit1810. In breast cancer cells, 
PADI2 but not PADI3 or PADI4 specifically catalyze R1810 citrullination. Inhibition or 
depletion of PADI2 compromises transcription of thousands of highly expressed genes, 
as monitored by mRNA-seq analysis. Many of these PADI2-dependent genes are 
involved in key biological functions including RNAP2 transcription and cell 
proliferation. In chromatin RNA-seq, we found that PADI2 is mainly involved in active 
transcription, leading us to conclude that PADI2 participates in facilitating active 
transcription. However, in mRNA-seq analysis we also find genes up-regulated upon 
PADI2 depletion. Their up-regulation could be an indirect consequence of changes in 
the expression of PADI2-dependent genes or could be related to the need of R1810 
dimethyation for proper transcription termination (Zhang et al., 2016). This remains to 
be directly demonstrated.  
 
The previously reported asymmetrical (Sims et al., 2011) and symmetrical 
(Zhang et al., 2016) dimethylation of R1810 occurs mainly in hypo-phosphorylated 
RNAP2, as detected only after phosphatase treatment. In contrast, we find that cit1810 
is preferentially associates with the transcriptionally engaged phosphorylated RNAP2. 
Depletion of the methyltransferases responsible for R1810 dimethylation, CARM1 and 
PRMT5, did not affect the expression of PADI2 dependent genes, and depletion of 
PADI2 did not change the expression of a broad range of snRNAs, the targets of 
CARM1. As PADI2 can not act on methylated R1810, and citrullination will preclude 
methylation by arginine methyltrasferases, its seems that these are alternative types of 
modifications influencing different stages of transcription, as observed in other arginine 
residues that can undergo methylation and citrullination (Tanikawa et al. 2018; Cuthbert 
et al., 2004). This implies the dynamic nature of R1810 modifications, that change the 
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docking surface for regulatory protein complexes to control various phases of 
transcription.  
 
Our results of RNAP2 ChIP-seq show that PADI2 mediated cit1810 is required 
for RNAP2 pause release or high turnover (Krebs et al., 2017) at promoters of highly 
expressed genes that maintain cellular proliferation (Day et al., 2016; Gilchrist et al., 
2010; Zeitlinger et al., 2007). In search for the molecular mechanism, we found that 
PADI2 interacts with the P-TEFb kinase complex, which is needed for RNAP2 pause 
release and productive transcript elongation. This interaction depends on R1810, 
supporting a function of cit1810 to facilitate transcription. Most likely, citrullination of 
R1810 at RNAP2-CTD is the key mechanism to maintain the transcription level of 
highly expressed genes involved in tumor progression and metastasis, essentially 
needed to overcome the RNAP2 pausing. This assumption is coherent with the recent 
findings that inhibition of PAD2 activity suppress the mammary gland tumor invasion 
in mice (Horibata, S., et al., 2017) and reduces the mammary cancer progression in dogs 
and cats (Ledet., M.M et al., 2018). Remarkably, PADI2 null mice are viable (Van 
Beers et al. 2013), suggesting that PADI2 mediated cit1810 RNAP2-CTD is not needed 
during normal development or that this function is fulfilled by another member of the 
PADI family. This last possibility seems unlikely, as by modeling the structure of 
PADI2 with the bound R1810 CTD peptide, we identified essential PADI2-specific 
amino acid residues that are not conserved in other PADI family members.   
 
Although our results support a function of PADI2 mediated citrullination  of 
CTD R1810 in transcription elogation, we cannot exclude an pleiotropic action of  
PADI2 on other substrates, including citrullination arginine 26 at histone H3 (H3R26),  
which  could be involved in local chromatin decondensation and transcription activation 
(Zhang et al. 2012). Another intriguing open question concerns the implications of the 
proposed irreversibility of the citrullination reaction (Cuthbert et al., 2004; Wang et al., 
2004). In the absence of enzymes that erase citrullination, alternative mechanisms may 
exit to replace the citrullinated RNAP2 before reaching transcription termination. Given 
that arginine-mediated interactions between intriniscally disordered protein domains, 
including the CTD of RNAP2, and RNAs or Poly(ADP-Ribose) are important in the 
formation of liquid droplets within the cell nucleus (Altmeyer et al. 2015; Hnisz et al. 
2017; Harlen et al., 2017), we cannot exclude that citrullination of R1810 could also 
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participate in modulating this interactions, and those influencing transcritional output. 
Further work will  be required to  investigate  these  possibilities. 
 
Many elongation factors and kinases are implicated in the control of RNAP2 
transcription pause release, a mechanism that controls the expression of genes involved 
in cancer progression and metastasis, like CDK9, MYC, JMJD6 (Zhang et al., 2017; 
Bywater et al., 2013; Miller et al., 2017). PADI2 is also found overexpressed in breast 
cancer (Cherrington et al., 2012) and other cancers (Guo et al., 2017). Indeed, we found 
that PADI2 depletion or mutation of R1810 reduced cell proliferation of breast cancer 
cells, by modulating cell cycle progression. Also, among PADI family members, only 
PADI2 is overexpressed in breast cancer and other cancers and its overexpression 
correlates with poor prognosis (Cherrington et al. 2012; Curtis et al., 2012; Richardson 
et al., 2006; Cancer Genome Atlas Network. et al., 2012; Adib et al., 2004; Brune et al., 
2008; Cho et al., 2011; Compagno et al., 2009; Hou et al., 2010; Murat et al., 2008; 
Gyorffy et al., 2010; Gyorffy et al., 2013; Szász et al., 2016; Vathipadiekal et al., 2015). 
Thus, our finding opens the possibility that specific inhibition of citrullination at 
R1810-RNAP2 may represent a suitable drug target. 
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MAIN FIGURE TITLES AND LEGENDS 
 
Figure 1 (With related Figure S1). Citrullination of R1810 at RNAP2-CTD. (A). 
Top: the epitope within repeats 31/32 of the CTD domain of RNAP2 used to generate 
α-Cit1810. Bottom: duplicated western blot of T47D nuclear extract with α-Cit1810 
and α-total-RNAP2. Line on the left mark the migration of the 250 kDa size marker.  
(B). Extracts from T47D cells expressing α-amanitin resistant WTr or R1810Ar mutant 
of RNAP2 were precipitated with α-HA antibody and probed with α-Cit1810 or α-
RNAP2. (C). Representative super-resolution images of T47D cells immunostained 
with α-Cit1810 (red) in combination with α-total-RNAP2 (green), α-S2P-RNAP2 
(green) and α-S5P-RNAP2 (green). (D) Plot representing the mean Pearson correlation 
coefficient of individual cells for α-Cit1810-RNAP2 with α-total-RNAP2 (n=22), α-
S2P-RNAP2 (n=24) and α-S5P-RNAP2 (n=24); values presented as the mean ± SEM. 
** p-value < 0.005; º p-value > 0.05. 
Figure 2 (With related Figure S2). PADI2 citrullinates R1810 at RNAP2-CTD. (A) 
Bar plot showing the normalized reads of PADI gene family members from two RNA-
sequencing experiments performed in T47D cells. The normalized reads are represented 
relative to ACTB1 gene. Values are means ± SEM. Inset-western blots performed on 
T47D nuclear extract with antibodies to PADI2, 3, 4 and Tubulin. (B) Nuclear extracts 
from T47D cells transfected with siRNA control (siCTRL) or siRNA against PADI2 
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(siPADI2) are probed with α-Cit1810, α-total-RNAP2, α-PADI2 and α-PADI3. (C) 
Top: Coomassie blue staining of SDS-PAGE with recombinant GST-tagged, GST-N-
CTD and GST-C-CTD proteins used for the citrullination assay. Bottom: In vitro 
citrullination immunoblot with or without recombinant PADI2 (rPADI2) using as 
substrate the N-terminal half of the CTD containing R1603 (lanes 3 & 4) or the C-
terminal half containing R1810 (lanes 5 & 6), both linked to GST. As a control, GST 
was also tested (lanes 1 & 2). (D) Microscale thermophoresis assay showing the affinity 
of recombinant PADI2 for the indicated wild -type and modified CTD-RNAP2 peptides 
encompassing the R1810. Y-axis represents the binding affinity as normalized 
fluorescence (Fnorm, see methods). (E-F) Immunoprecipitation with (E) α-PADI2 (F) 
α-S2P/S5P RNAP2 or non-immune mouse or rabbit IgG of T47D extracts followed by 
western blot with the indicated antibodies. 
 
Figure 3 (With related Figure S3).  PADI2 mediated cit1810 at RNAP2-CTD 
regulates transcription and cell proliferation in breast cancer cells. (A) Volcano 
plot showing genome-wide mRNA changes after PADI2 depletion from biological 
replicates. The X-axis represents log2 expression fold changes (FC) and the Y-axis 
represents the adjusted p-values (as -log10). Differentially expressed genes (FC > 1.5 or 
<1/1.5 and p value < 0.01) are shown, the positions of PADI2 and genes used for 
validation are also indicated. (B) Quantitative RT-qPCR validation in T47D cells 
transfected with siCTRL, siPADI2 and siPADI3. Changes in mRNA levels were 
normalized to GAPDH mRNA. Data represent mean ± SEM of at least three biological 
experiments as in other plots in the figure. (C) Volcano plot showing genome-wide 
chromatin associated RNAs changes before and after PADI2 depletion from 
independent replicates. The X-axis represents the log2 fold changes (FC) and the Y-axis 
represents the adjusted p values (-log10). The dotted line indicates the cutoff p value < 
0.01. Differential expressed genes (FC > 1.5 or 1/1.5 and the p value < 0.01) are shown. 
(D) Browser snapshots of SERPINA6 gene in T47D cells showing chromatin associated 
RNAs sequencing profile (orange) and mRNA sequencing profiles after PADI2 
knockdown (blue) and expressing WTr and R1810r mutant form of RNAP2 (Green). 
Scale is indicated on the top of the gene. (E) Quantitative RT-qPCR on chromatin 
associated RNA (ChrRNA) in T47D cells transfected with siCTRL, siPADI2 RNAs. 
Data normalized to GAPDH ChrRNA expression level. (F) T47D cells expressing only 
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α-amanitin resistant HA tagged WTr or R1810Ar mutant form of RNAP2 were used for 
quantitative RT-qPCR of mRNA from PADI2 dependent genes (SERPINA6, c-MYC 
and HMGN1), and for control genes (GSTT2 and LRRC39). (G) Cell proliferation of 
T47D cells in the absence (siCTRL or DMSO) or presence of PADI2 depletion 
(siPADI2), PADI2 inhibitor (Cl-amidine in DMSO) and of cells expressing α-amanitin 
resistant HA tagged WTr and R1810Ar mutant form of RNAP2. (H) Left: Venn diagram 
showing the set of genes related to cell cycle (GO:0007049 (n= 315, Out of them 282 
genes expressed in T47D cells) that are down-regulated in T47D cells expressing the 
R1810Ar mutant of RNAP2 in comparison to WTr RNAP2 (R1810 dependent) versus 
R1810 independent gene (see Table S2). Right: Box plot showing log2 fold change 
(R1810Ar / WTr RNAP2) for R1810 dependent and independent cell cycle genes. Each 
box in the panel represents the interquartile range; Whisker extends the box to the 
highest and lowest values, horizontal lines indicate the median value. Dependent genes 
showed significant lower mRNA levels than independent genes (***p-value < 0.0001, 
calculated by Wilcoxon-Mann-Whitney test).  
Figure 4 (With related Figure S4).   PADI2 occupancy on active genes. (A) Left: 
Spie chart showing the distribution of PADI2 ChIP-seq peaks over various genomic 
regions. A dashed curved line indicates the region from 3kb upstream of TSS to 3kb 
downstream of TTS (or Polyadenylation site); the numbers in parenthesis show the 
proportion occupied by each region in the genome. Right: Enrichment of normalized 
PADI2 reads in various genome regions relative to random distribution (* p-value <10-
2; ** p-value <10-3; *** p-value <10-4). (B) Distribution of normalized PADI2 reads 
around the center of RNAP2 peaks in T47D cells. (C) RNAP2 and PADI2 occupancy 
across genes classified with increasing levels of expression. p-value was calculated by 
Wilcoxon-Mann-Whitney test in comparison to silent genes as indicated (** p-value < 
10-3; *** p-value < 10-5).  
 
Figure 5 (With related Figure S5).   Cit1810 at CTD-RNAP2 regulates pausing in 
breast cancer cells. (A) RNAP2 ChIP qPCR assay performed in T47D cells expressing 
only the HA-tagged wild-type (WTr) or R1810Ar mutant of RNAP2 with the HA 
antibody. Non-immune IgG was used as negative control. Y-axis: fold change over the 
input samples. (B-C) Difference in RNAP2 density in T47D cells expressing HA-
tagged R1810Ar mutant versus WTr   RNAP2 (B) across genes classified by expression. 
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(C) Pausing index of RNAP2 as indicated. (D-E) PADI2 dependent genes (n=2,186) 
showing (D) Left: average profile of difference in RNAP2 density (R1810Ar -WTr) 
around TSS. Right: heat map at TSS of genes ranked from highest to lowest RNAP2 
density (R1810Ar -WTr). (E) Higher pausing index in cell expressing R1810Ar mutant 
as compared to WTr   form of RNAP2. (F) Browser snapshots showing RNAP2 
occupancy for HMGN1 & control gene LRRC39 in cells expressing HA-tagged WTr or 
R1810Ar form of    RNAP2.  
 
Figure 6. Cit1810 at RNAP2-CTD is recognized by P-TEFb. (A) 
Immunoprecipitation with α-CDK9 (Left) α-PADI2 (Right) or non-immune rabbit IgG 
of T47D extracts followed by western blot with the indicated antibodies. (B) Extracts 
from T47D cells in the presence (siCtrl) or absence (siPADI2) of PADI2 were 
immunoprecipitated with α-total-RNAP2 followed by western blot for the indicated 
antibodies along with relative quantifications underneath. (C-D) Immunoprecipitation 
of extracts from (C) T47D (D) Raji cells expressing only the HA-tagged α-amanitin 
resistant WTr or R1810Ar mutant of RNAP2 were precipitated with α-HA antibody and 
probed with the indicated antibodies. The relative quantification is shown underneath 
each gel. (E) (Top) Schematic representation of the pull-down assays with T47D 
nuclear extracts and RNAP2-CTD biotinylated peptides (wild type R1810 or cit1810). 
(Bottom) Results of the pull-down experiments with wild type (R1810) or cit1810 
biotinylated RNAP2-CTD peptides shown as western blots probed with the indicated 
antibodies against CDK9 and CCNT1. Quantification of the increase with the Cit1810 
relative to the wild type R1810 is shown underneath. (F) Average profile of CDK9 
density around TSS in ChIP-seq experiments using CDK9 antibody in T47D cells 
expressing the HA-tagged wild-type (WTr) or R1810Ar mutant of RNAP2 and 
difference (R1810Ar - WTr) across genes classified by expression level. Black line 
representing signal difference from random regions. (G) Left panel: Similar as in (F) for 
PADI2 dependent genes versus nondependent genes (siPADI2/siCTRL, FC<1.5; FC> 
1/1.5, p-value > 0.05). Right panel: Box plot showing average difference in CDK9 
profiles in PADI2 dependent versus non-dependent genes. p-value calculated by 
Wilcoxon-Mann-Whitney test. (H) Fold change over input in CDK9-ChIP qPCR assay 
on the promoter region of three PADI2 dependent genes (SERPINA6, c-MYC, HMGN1) 
and two non-dependent genes (GSTT2, LRRC39) in T47D cells expressing the HA-
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tagged wild-type (WTr) or R1810Ar mutant of RNAP2. Values are means ± SEM. * p-
value < 0.05; ** p-value < 0.01; º p-value > 0.05.  
Figure 7 (With related Figure S6-S7).  Illustration of structural model of PADI2 
with R1810 at RNAP2-CTD. (A) Close-up of the peptide binding site of PADI2 shown 
in cartoon and surface representation (green) and R1810 CTD- RNAP2 peptide in 
ribbon (magenta) and stick representation of side-chains (colored by atom type: 
Oxygen: red; Nitrogen: blue; C: grey) of amino acid selected for mutation studies: non-
conserved (ARG580, LEU642, shown in orange) and conserved (ASP374, SER401, 
shown in blue). (B) Box-plot showing the distribution of Rosetta Scores for the top 200 
structural models performed for PADI2 and PADI3 proteins complexed with R1810 
peptide. Central horizontal lines in the box mark the median and box edges of the first 
(Q1) and third (Q3) quartiles; top and bottom errors bars mark the Q1 and Q3 +1.5x 
interquartile range respectively; outliers are shown as empty circles. (C) In vitro 
citrullination immunoblot using the C-terminal CTD half containing R1810 as substrate, 
in absence (lane 2) or presence of recombinant PADI2 as wild-type (WT, lane 2) and 
PADI2 mutants of conserved residues (D374K and S401A lane 3 and 4) and of PADI2 
unique residues (R580E and L642T, lane 5 and 6).  (D) Proposed model of Cit1810 
function in transcription. PADI2 catalyzed R1810 to the Cit1810 at RNAP2-CTD, 
facilitate association with P-TEFb (CDK9-CCNT1) complex and hence overcome 
RNAP2 accumulation and leads to an increase in transcription and cell proliferation.  
 
 
CONTACT FOR REAGENT AND RESOURCE SHARING 
Further correspondence and requests for reagents should be directed to and fulfilled by 
the Lead Contact Miguel Beato (miguel.beato@crg.eu).  
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS  
Cell lines 
T47D, MCF, and Raji cells were grown routinely in their optimal medium according the 
ATCC recommendations. T47D cell line carrying a single copy of luciferase reporter 
gene driven by MMTV promoter (T47D-MTVL, Truss et al., 1995) were grown in 
RPMI-1640 medium without phenol red supplemented with 10% dextran coated 
charcoal treated FBS (DCC/FBS), 2mM L-glutamine, 100U/ml penicillin-streptomycin 
as reported previously (Vicent et al., 2009; Wright et al., 2012). MCF7 cells were grown 
in DMEM (without phenol red) with 10% DCC/FBS and 100U/ml penicillin-
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streptomycin. All cell transfections were carried out using Lipofectamine 3000 
(Invitrogen) according to manufacturer’s instructions. Cells were treated with 200µM 
citrulline inhibitor Cl-amidine (506282, Calbiochem) or vehicle (DMSO) for 2 hours. 
T47D cells (2.5x106 cells per 8µg plasmid) were transiently transfected with HA tagged 
α-amanitin resistant wild-type (WTr) or R1810Ar RNAP2 plasmids for 24 hours 
followed by α-amanitin (A2263, Sigma Aldrich, 6ug/ml) treatment for 12 hours to 
inhibit endogenous RNAP2.  
 
Raji cells with stable expression of HA tagged WTr or R1810Ar RNAP2 plasmids DNA 
were generated by electroporation (condition 250V and 950µF; 2x107 cells per 10µg 
plasmid DNA) followed by selection with G418 (000000004727878001, Sigma 
Aldrich,1mg/ml) and Doxycycline (D9891, Sigma Aldrich, 0.1ug/ml). To induce the 
expression of recombinant RNAP2 cells were grown in tetracycline-free complete 
medium for 48 hours prior to doxycycline (D9891, Sigma Aldrich) addition at a 
concentration of 0.1ug/ml. Endogenous RNAP2 was subsequently inhibited using α-
amanitin (2ug/ml) for 24 hours before downstream assays. 
 
 
 
METHODS DETAILS  
Experimental procedures  
Antibodies  
Generation of anti-Cit1810 RNAP2-CTD Antibody: The citrulline specific antibody 
was raised in rabbits by Eurogentec using a KLH coupled CTD peptide sequence 
(YSPSSP-cit-YTPQSP). Affinity purification was performed first on a column 
containing the citrullinated peptide, followed by removal of non-citrullinated specific 
antibodies on a column containing the non-citrullinated peptide. 
 
Commercial antibodies used in this study were as follows: anti-PADI2 for ChIP and 
Immunoprecipitation assays : (sc-133877 lot no # E1214 and H0715, Santa Cruz Biot.); 
anti-PADI2 for western blots and Immunofluorescence  (12110-1-AP from Proteintech 
and WH0011240M1 from Sigma); anti-citrulline (AB5612, Millipore), anti-citrulline 
detection kit (17-347, Millipore,), anti-CARM1 (09-818, Millipore), anti-PRMT5 (07-
405, Millipore), anti-TUBULIN (T9026, Sigma ), anti-GAPDH (sc-32233, Santa Cruz 
Biot.), anti-PADI4 (ab50247, Abcam), anti-PADI3 (sc-393622, Santa Cruz Biot), anti-
HA (ab9110, Abcam), anti-RNAP2  for ChIP (CTD4H8,05-623, Millipore; Rpb1 NTD 
(D8L4Y), 14958, Cell Signaling), for western blot (N-20, sc-899, Santa Cruz Biot.), 
anti-phospho-S2 RNAP2 CTD (3E10, 04-1571 from Millipore), anti-CDK9 (H-169, 
SC-8338,lot no # C0415), anti-CCNT1(A303-499A,Bethyl Labs), IgG negative control 
for ChIP and immunoprecipitation assays (12-371, Millipore; 2729S Cell Signalling). 
Anti-S2P-RNAP2 (CMA602, MBL Life science) and anti-S5P-RNAP2 (CMA603, 
MBL Life science) were kindly provided by Hiroshi Kimura´s laboratory. 
 
Peptides: All peptides were synthesized and purified by Eurogentec. The CTD peptide 
PSYS2PSS5PRYT2PQS5PTYT2P was used for dot blots, and microscale thermophoresis  
(MST) experiments, either unmodified (CTD-WT) or with Cit1810, R1810me2a, S2-P 
(1805,1812,1819) or S5-P (1808, 1815) modifications. The N-terminal biotin labeled 
CTD peptides (CTD-WT with R1810) PSYS2PSS5PRYT2PQS5PTYT2P and (CTD-
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cit1810) PSYS2PSS5PcitYT2PQS5PTYT2P were used for pull down assay. Peptides 
were quantified by amino acid analysis, and the presence of the modifications was 
confirmed by mass spectrometry.  
 
Plasmids: The α-amanitin resistant HA-tagged wild-type (WTr) or R1810Ar mutant 
RNAP2 plasmids were previously published (Meininghaus et al., 2000; Sims et al. 
2011). The GST-N-CTD (repeats 1-25.5), the GST-C-CTD (repeats 27-52) of RNAP2 
were kindly provided by David Bentley (Bentley et al., 1999).  
 
RNA interference experiments: For siRNAs inhibition experiments T47D or MCF7 
cells were transfected with 100µM siRNA using Lipofectamine 3000 (Invitrogen) for 
72 hours according to manufacturer´s instructions. SMARTpool On-target plus siRNAs 
for PADI2 (M-019485-01) and PADI3 (M-021051-01) from Dharmacon (Thermo 
Scientific). siRNAs for CARM1 (sc-44875), PRMT5 (sc-41073) and PADI4 (sc-61283) 
from Santa Cruz Biot.  
 
Chromatin RNA extraction: Chromatin RNA from T47D cells transfected with either 
siCTRL or siPADI2 was prepared as described previously (Nojima et al., 2016). Briefly, 
T47D cells transfected with siCTRLor siPADI2 were lysed for 5 minutes in 4ml of ice-
cold HLB+N [10mM Tris-HCl pH 7.5, 10mM NaCl, 2.5mM MgCl2 and 0.5% (vol/vol) 
NP-40], followed by addition of 1ml of ice cold HB+NS buffer [10 mM Tris-HCl pH 
7.5, 10mM NaCl, 2.5mM MgCl2, 0.5% vol/vol, NP-40 and 10% wt/vol sucrose]. Cell 
nuclei were collected by centrifugation at 1,400rpm for 5 minutes at 4°C, resuspended 
in 125µl of NUN1 buffer [20mM Tris-HCl pH 7.9, 75mM NaCl, 0.5mM EDTA and 
50% vol/vol glycerol]. After addition of 1.2 ml of ice cold NUN2 buffer [20mM 
HEPES-KOH pH 7.6, 300mM NaCl, 0.2mM EDTA, 7.5mM MgCl2, 1% vol/vol NP-40 
and 1M urea], samples were incubated on ice for 15 minute, mixing by vortexing every 
3 minutes. The chromatin pellet was resuspended in HSB buffer [10mM Tris pH 7.5, 
500mM NaCl and 10mM MgCl2] and treated with TURBO™ DNase (AM2239, 
Thermo Scientific) at 37˚C for 15 minutes, followed by Proteinase K (AM2546, 
Thermo Scientific) for 10 minutes at 37˚C. Chromatin-RNA was purified by Trizol 
(Thermo Scientific), quantified with a Qubit 3.0 Fluorometer (Life Technologies).  
 
RNA extraction and RT-qPCRs: RNA from T47D cells transfected with either 
siCTRL or siPADI2 and expressing α-amanitin resistant HA-tagged wild-type (WTr) or 
R1810Ar mutant RNAP2 was extracted using RNeasy (Qiagen) according to 
manufacturer´s instructions. 1µg of purified RNA was used for DNase treatment 
(Thermo Scientific), quantified with a Qubit 3.0 Fluorometer (Life Technologies).  
 
Reverse transcription was performed for chromatin RNA with random hexamers, for 
RNA with oligo (dT) using SuperScript III (Invitrogen) according to manufacturer´s 
instructions. Complementary DNA was quantified by qPCR using Roche Lightcycler 
(Roche), as previously described (Vicent et al., 2009). For each gene product, relative 
RNA abundance was calculated using the standard curve method and expressed as 
relative RNA abundance after normalizing against the human GAPDH gene level. All 
the gene expression data generated by RT-qPCR represent the average and SEM of at 
least 3 biological replicates. Primers used for RT-qPCR are listed in Table S4. 
 
PolyA RNA-seq 
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Purified RNA was analyzed on Bioanalyzer using an RNA Pico assay chip. PolyA plus 
RNA mRNA libraries were prepared using TruSeq Stranded RNA Library Prep Kit 
(Illumina) and sequenced using Illumina HiSeq 2500. 
 
Chromatin RNA-seq 
Chromatin associated RNA was prepared as mentioned above (Nojima et al., 2016). 
Before preparing chromatin RNA libraries, contaminant of rRNAs was depleted using 
Ribo-Zero rRNA removal kit. Libraries were prepared using TruSeq Stranded small 
RNA Library Prep Kit (Illumina) and sequenced using Illumina HiSeq 2500. 
 
Protein extract preparation, Co-immunoprecipitation (IP), Peptides pull down, 
and Western blots: Cells were prepared as described previously (Wright et al., 2012). 
Briefly, 5 x 106 to 107 cells were lysed on ice for 30 minutes in lysis buffer (1% Triton 
X-100 in 50mM Tris pH 7.4-7.6, 130mM NaCl) containing proteases inhibitors 
(11836170001, Roche) with rotation, followed by sonication for 7 minutes with every 
30 seconds on and 30 seconds off. After centrifugation at 4ºC and 13,000rpm for 10 
minutes, extracts were used for protein quantitation. For IP 2mg of extract were 
incubated for 12 hours with protein G/A agarose beads (for rabbit antibodies, IP05, 
Millipore) or Dynabeads™ M-280 Sheep Anti-Mouse IgG (for mouse antibodies, 
11201D, Thermo Scientific), previously coupled with 5-7µg of the corresponding 
antibodies or a control IgGs. For RNAP2-S2P and -S5P 7µg of each mouse monoclonal 
antibodies (CMA602 or CMA603, respectively) were coupled with Dynabeads, 
followed by 12 hours’ incubation with extract at 4ºC. The samples were washed 6 times 
with lysis buffer and boiled for 5 minutes in SDS gel sample buffer. For detection of 
mentioned proteins of molecular weight (<200 kDa) 4-12% SDS-PAGE gels were used; 
while for the RNAP2 large subunits (> 200kDa), we used 3-8% SDS-PAGE.  
 
For peptide pull down assay, 100µg of each CTD-WT (with R1810) and CTD-cit1810 
biotin labeled peptides were bound to 100µl of the Dynabeads™ MyOne™ Streptavidin 
T1 (65601, Thermo Scientific) in 1ml of binding buffer [150 mM NaCl, 50 mM Tris pH 
8, 1% IGEPAL CA-630] by rotation at room temperature for 2 hours. The peptide 
bounds Dynabeads were incubated with 300µg of T47D cells nuclear extract for 12 
hours’ at 4ºC along with rotation. Peptide bound protein complexes were then washed 
five times with wash buffer [400 mM NaCl, 50 mM Tris pH 8, 1% IGEPAL CA-630] 
followed by two washes with binding buffer. All buffers were supplemented with 
freshly prepared protease inhibitors. Samples were eluted by incubation at 70ºC for 5 
minutes in SDS gel sample buffer, followed by protein detection of mentioned proteins 
by western blots. 
 
For Western blots primary antibodies were used at 1:250 to 1:1000 dilution (for 
α−cit1810; 1:50) and incubated overnight at 4ºC, followed by an hour incubation with 
horseradish peroxidase conjugated anti-mouse (NA931V) or anti-rabbit (NA934V, 
Amersham) and blots were developed using ECL prime Western blotting detection 
reagent (RPN2232, GE Healthcare) according to the manufacturer instructions. 
 
Size exclusion chromatography: The size exclusion chromatography of T47D cell 
extracts were carried out using Superdex 200 10/300mm columns (17517501, GE 
healthcare). As per manufacturer´s instructions, for high molecular weight (Ferritin ,440 
KDa) and for low molecular weight (Conalbumin,75 KDa & Carbonic anhydrase 
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29KDa) were run along with cell extracts. Samples were chosen according to 
chromatography profile and used for Western blots.  
BrdU (5´-bromo-2´-deoxyuridine) cell proliferation assay: T47D cells (1 × 104) were 
plated in a 96-well plate followed by transfection with control/ PADI2 siRNAs or 
treated with the PADI inhibitor Cl-amidine at concentration of 200µM or DMSO or 
expressing α-amanitin resistant HA-tagged wild-type (WTr) or R1810Ar mutant form of 
RNAP2.The cell proliferation ELISA BrdU Colorimetric assay (Roche,11647229001) 
was performed as per manufacturer's instructions. The experiments were performed at 
least four biological replicates.  
 
Fluorescence-activated cell sorting (FACS) experiments: FACS assay was 
performed in T47D cells transfected with control or PADI2 siRNAs from three 
biological replicates. Briefly, cells were trypsinized, washed three times with 1x PBS 
and fixed with cold absolute ethanol in suspension at 70% final concentration. Cells 
were stained with propidium iodide (P-1304, Molecular Probe) followed by DNase I 
(RNase-free) (AM2222, Thermo Scientific) treatment and stored for 24 hours at 4ºC 
and DNA contents of cell cycle phases were analyzed using a BD™ LSR II flow 
cytometer.  
 
In vitro citrullination assay with recombinant PADI2 wild-type and mutants 
(D374K, S401A, R580E, and L642T) and fragments of the RNAP2-CTD: The 
PADI2 open reading frame (ORF) was cloned into the HIS-tagged expression vector 
pCoofy1 (Addgene, 43974) and the wild-type (WT) plasmid sequence were verified. All 
four PADI2 mutants were generated by using WT PADI2 plasmid by performing site-
directed mutagenesis as directed in Quick change mutagenesis kit and mutations were 
confirmed by sequencing. The mutagenic primers given in Key Resource Table.   
 
Recombinant proteins were expressed in bacteria strain BL21 pRARE and purified 
following the standard method of histidine-tagged recombinant protein. Briefly, cells 
were lysed in Buffer A (50mM Tris HCl pH7.4, 500mM NaCl, 10% glycerol, 2mM 
DTT, 20mM Imidazole, 1% and triton X-100) complemented with proteinase inhibitors 
(11836170001, Roche). Purification was performed using the HiTrap TALON crude 
(28953766, GE Healthcare) according to manufacturer´s instruction. Proteins eluted in 
buffer containing 50mM Tris-HCl pH 7.4, 300mM NaCl and 10% glycerol, were stored 
at -80ºC until required. The GST-N-CTD (repeats 1-25.5), GST-C-CTD (repeats 27-52) 
of RNAP2 were expressed and purified following the standard glutathione bead 
purification (Bentley et al., 1999). In vitro citrullination was carried with recombinant 
His-PADI2 in deimination buffer (50mM HEPES pH 7.5, 10mM CaCl2, 4mM DTT) at 
37 ºC for 1hour. Samples were dissolved in sample Laemmli buffer for immunoblot 
analysis using an anti-citrulline antibody (Christophorou et al., 2014; Wang et al., 
2004), Millipore,17-347).     
 
 
Microscale Thermophoresis (MST) of recombinant PADI2 with RNAP2-CTD 
peptides: Wild-type peptide or peptides carrying modifications of R1810me2a CTD, 
S2P-CTD and S5P CTD (20nM to 500µM) were titrated against a fixed concentration 
of fluorescent recombinant His-PADI2 (50nM). MST data were acquired at 20°C using 
the red LED at 20% and IR- Laser at 40% using a (Monolith NT.115, Nano Temper 
Technologies) according to manufacturer’s instructions. The results are plotted as 
 31 
normalized fluorescence (Fnorm, representing binding affinity) against the 
concentration of the unlabeled ligand and fitted according to the law of mass action. 
 
Immunofluorescence, image acquisition and analysis: T47D cells were grown on 
round 10mm glass coverslips transfected with sicontrol or siPADI2 prior to fixation 
with 4% paraformaldehyde in PBS for 5 minutes and permeabilized with PBS 0.1% 
Triton X-100 (PBST) at room temperature for 5 minutes. Coverslips were blocked with 
IF buffer (5% BSA, 0.1%Triton X-100 in PBS) for 20 minutes at room temperature and 
incubated overnight with primary antibodies diluted in IF buffer at 1:50 of α-Cit1810 
(Rabbit), 1:50 of α-CTD4H8 (mouse, Santa Cruz Biot.) to detect the total RNAP2, 
1:250 of α-S2P-RNAP2 (mouse, CMA602) and 1:250 of α-S5P-RNAP2 (mouse, 
CMA603). For triple staining 1:500 of α-PADI2 (Mouse, WH0011240M1, Sigma) was 
used with 1:50 of α-Cit1810 along with α-S2P-RNAP2 (3E10; Rat, Millipore; Figure 
S2I). For Figure S1G, α-HA (1:250, ab9910; Rabbit) and α-RNAP2 (1:50, CTD4H8; 
mouse, Santa Cruz Biot.). After 3x washes with PBST (1X PBS with Triton X-100 0.1 
%) samples were incubated with secondary antibodies at a dilution 1:500 (AlexaFluor 
594 anti-rabbit, AlexaFluor 488 anti-mouse or AlexaFluor 680 anti-mouse and 
AlexaFluor 488 anti-rat, Invitrogen-Molecular Probes) for 1h at room temperature 
followed by three washes with PBST. Samples were mounted with Mowiol mounting 
medium. For quantification, DAPI (4 ', 6-Diamidino-2-Phenylindole, Dihydrochloride)	
or	Hoechst fluorescent stains were used as reference. Confocal images of T47D cells 
(Figure S1G and Figure S2B) were acquired with a Leica SP5 (DMI 6000) inverted 
microscope using an HCX PLAN APO λ blue 63x/1.4-0.6 Oil immersion lens, PMT 
detectors and diode and Argon lasers. Laser and spectral detection bands were chosen 
for the optimal imaging of Alexa 488, Alexa 594 and DAPI to obtain Z-stacks of 
nuclear optical sections at a distance of 0,42µm. 
Super-resolution images were acquired with a Leica SP8 STED 3X microscope using a 
HC PL APO CS2 100x/1.4 Oil immersion lens, a pulsed supercontinuum light source 
(white light laser) and HyD detectors, using the Leica acquisition software. Laser and 
spectral detection bands were chosen for the optimal imaging of nuclear optical sections 
with a z-distance of 0. 16µm. Deconvolution was performed using the Huygens 
deconvolution software (Scientific Volume Imaging, SVI) for STED modes using shift 
correction to account for drift during stack acquisition. Adjustments of individual 
channels were applied to the whole image, pseudo-coloring, cropping and different 
channel composite images were done with FIJI (https://www.fiji.sc, Schindelin et al. 
2012  ). Raw cropped images were used to calculate the correlation of the fluorescent 
signal with R version 3.4.1 (https://www.R-project.org/ R core team, 2017). All images 
were imported to the R with the package EBImage (Pau et al., 2010). 
ChIP-qPCRs: For ChIP assays (Vicent et al. 2014), 10 x 106 of T47D cells, transfected 
with either siCTRL or siPADI2 and expressing α-amanitin resistant HA-tagged wild-
type (WTr) or R1810Ar mutant RNAP2 were cross-linked for 10 minutes with 1% 
formaldehyde. The lysate was sonicated to a DNA fragment size range of 200-300bp 
using a Biorupter sonicator (Diagenode). PADI2 was immunoprecipitated with 6µg of 
PADI2 antibody (z-22):sc-133877 lot number E1214 and H0715 using 50 µg of 
chromatin and 42µl of Protein A-Agarose Beads (Diagenode). For RNAP2, 150 µg   
chromatin was incubated with 20µg of antibody (Rpb1 NTD (D8L4Y), 14958, Cell 
Signaling; CTD4H8, Millipore), 15µg of anti-HA (ab9110) for HA-tagged wild-type 
(WTr) or R1810Ar mutant form of RNAP2, 15µg of anti-CDK9 (H-169, SC-8338, lot 
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no # C0415),  20µg of S2P; CMA602 and S5P; CMA603) or control IgG in IP Buffer 
with 2X SDS buffer (100mM NaCl, 50mM TrisHCl, pH8, 5mM EDTA and 0.5% SDS) 
and 1X Triton buffer (100mM Tris-HCl, pH8.8, 100mM NaCl, 5mM EDTA and 5% 
Triton-X)   with protease inhibitors (11836170001, Roche) for 16 hours at 4º C. 
Followed by incubating with Protein A Sepharose beads CL-4B (17-0780-01, GE 
Healthcare) or 50µl of Dynabeads® M-280 sheep anti-mouse IgG (11201D, Thermo 
Scientific) for 3 hours. Beads were washed with 3 times with low salt buffer (140mM 
NaCl, 50mM HEPES, pH 7.4, 1% Triton-X 100), 2 times with high salt buffer (500 mM 
NaCl, 50mM HEPES, pH 7.4, 1% Triton-X 100) followed by single wash of LiCl 
Buffer (10mM Tris HCl pH 8.0, 250 mM LiCl, 1% NP-40, 1% sodium deoxycholic acid 
and 1mM EDTA) and 1X TE buffer in cold room. Subsequently, crosslinks were 
reversed at 65º C overnight, followed by RNAase treatment for 1.5 hours and bound 
DNA was purified by Phenol-Chloroform extraction. The resultant eluted DNA was 
quantified by Qubit 3.0 Fluorometer (Life technologies), and followed by real-time 
qPCR analysis and data represented as fold change over input fraction from at least 3 
biological replicate experiments. Primers used for RT-qPCR are listed in Table S4. 
 
ChIP-seq  
PADI2 and RNAP2 ChIP-purified DNA were analyzed on Bioanalyzer using DNA1000 
kit. At least 1ng of purified DNA were used to prepare ChIP-seq libraries using llumina 
ChIP Sample Library Preparation Kit. End repaired and adapter ligated libraries 
samples were size selected using E-Gel Size Select 2% Agarose Gel (Thermo Scientific, 
USA) followed by 13 cycles of PCR amplification. Barcode libraries from several 
samples were pooled and sequenced using Illumina HiSeq 2000 in single end 
sequencing run to obtain ~80–100 million reads.  
 
Bioinformatic Procedures   
 
RNA-seq Data processing  
Adapter sequences were remove from raw paired-end reads PolyA plus mRNA and 
ChrRNA raw paired-end reads by using Trimmomatic (Bolger et al. 2014) with the 
parameter values single-end mode, seed mismatches = 2, palindrome clip = 30, simple 
clip threshold = 12, min adapter length = 1, keep both reads, leading = 3, trailing = 3, 
target length =0, strictness = 999 and min length = 36. Transcript-level quantification 
was performed by Kallisto (Bray et al. 2016) by using 100 bootstraps. Spearman 
pairwise correlation (R2) between the two biological replicates (E1 and E2) were 
calculated, for the mRNA-sequencing siCTRL (R2=0.96), siPADI2 (R2=0.97), WTr 
(R2=0.98) and R1810Ar (R2=0.97) and for the ChrRNA-sequencing experiments 
siCTRL (R2=0.95) and siPADI2 (R2=0.93). 
 
Gene Expression Analysis  
Differential expression analysis was performed using DESeq2 Bioconductor package 
(Love et al., 2014). The analysis was performed by using 196,520 number of annotated 
transcripts of hg19 (correspond to 57,280 number of genes). Out of this, we quantitated 
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data for total 18,241 (mRNA seq) and 33,140 (ChrRNA seq) genes. Genes with FC < 
1.50 and adjusted p-value < 0.01 were considered as down-regulated and genes with FC 
> 1.50 and adjusted p-value < 0.01 as up-regulated (Figure 3A and 3C). 
ChIP-seq Data processing  
 
For ChIP-Seq data sets, first we performed the quality control analysis using fastQC 
tool with version GPLV3 (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). 
Single-ended sequences were trimmed to 50 bp and mapped to the human genome 
assembly hg19 using Bowtie (Langmead et al. 2009), keeping only tags that mapped 
uniquely and with no more than two mismatches. Fragment sizes were estimated using 
HOMER tools (Heinz et al. 2010). Normalized coverage profiles for regions of interest 
were obtained by using deepTools2 (Ramírez et al. 2016) with a 100bp bin size. 
 
RNAP2 and CDK9 ChIP-sequences were analyzed as mentioned previously (Iannone et 
al. 2015) by using MACS2 (Zhang et al. 2008)   with a FDR q-value<0.05. We noted 
that it typically results in regions with a very modest enrichment. Therefore, by default, 
we applied a more stringent threshold of FDR q-value<0.0001 and a 4-fold enrichment 
over the control sample to base the subsequent downstream analyses on a high-
confidence set of peaks. Because of broad peak of PADI2, significant enrichment to 
background compared to Input DNA were identified using SICER (Xu et al. 2014) with 
the following parameters: window size 200; fragment size 233 bp; gap size 600; and 
FDR 0.01. Genome-wide 10kb Spearman pairwise correlation of PADI2 ChIP-
sequencing signal was R2=0.98. We then applied ChIPpeakAnno R library (Zhu et al. 
2010) to create a merged list of peaks present in both replicates. ChIP-seq RPM 
normalized profiles were used to generate average profiles over different genomic 
features using bwtool (Pohl et al. 2014) deepTools2 (Ramírez et al. 2016) with a 100bp 
bin size. Similarly, ChIP-seq profiles from HA-tagged WTr and R1810Ar were obtained 
by deepTools2 with 100bp bin size and their difference (R1810Ar-WTr) was plotted by 
using in house custom R version 3.4.1 (R core team 2017) scripts on the indicates set of 
transcripts.  
 
 
Pausing Index (PI) of RNAP2 Analysis: RNAP2 pausing index was calculated as 
mentioned previously (Baranello et al., 2016; Zeitlinger et al., 2007; Chen et al., 2015). 
Briefly, RNAP2 pausing index represents the dynamics of RNAP2 assembly and 
promoter release and hence not only presence or absence of transcription. We calculated 
pausing index (PI) as the ratio of the RNAP2 read count 1kb (kilobase) flanking to the 
TSS divided by size and read count in the same gene body divided by the size of the 
gene body.   
 
Gene Ontology (GO) analysis: Go Annotation was performed using the online tool 
GSEA (Subramanian et al., 2005) (http://software.broadinstitute.org/gsea/index.jsp 
Gene Set Enrichment Analysis,) collection database v5. The significant cut off p-value 
and FDR q-value <0.05. All 315 genes documented with the parent cell cycle 
GO:0007049 
(http://software.broadinstitute.org/gsea/msigdb/cards/CELL_CYCLE_GO_0007049) 
were considered for analysis. Among them, 282 genes expressed in T47D cells; 101 
genes classified as PADI2 dependent (siCTRL/siPADI2 FC < 1/1.5, p-value < 0.01) and 
rest 181 genes as PADI2 independent (Figure 3H and Table S1). 
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Structural modeling of PADI2 and PADI3 with R1810 RNAP2-CTD complexes 
and conservation analysis. 
 
In the case of PADI2 (UniProt ID: Q9Y2J8), there are several crystallographic 
structures available in apo form in the PDB databank (Berman et al., 2000) and the one 
with PDB code 4N2I (Slade et al., 2015) was used to model the PADI2-R1810 RNAP2-
CTD complex. The structure of the apo-form of PADI3 (UniProt ID: Q9ULW8) was 
derived by homology modeling using M4T (Fuentes et al., 2007). PADI2 (PDB code: 
4N2G (Slade et al., 2015) was used as template sharing over 51% sequence identity 
with (coverage above 95%), hence optimal for homology modeling (Baker et al., 2001). 
The quality of the PADI3 model was assessed using ProSa2 (Sippl et al., 1993) and 
PROCHECK (Laskowski et al., 1993). 
 
The structural models of PADI2 and PADI3 bound to RNAP2 CTD peptide 
encompassing R1810 (sequence: YSPSSPRYTPQSPT) were derived using the pepspec 
application (King et al., 2010) in the Rosetta Suite (Fay et al., 2011) as follow. The 
structure of PADI4 in complex with histone H3 N-terminal tail (PDB code:2DEW, 
Arita et al., 2006) was used to position the central arginine of R1810 CTD RNAP2 
peptides, i.e. anchor residue, both in PADI2 and PADI3 structures. 100 models were 
generated, selecting the one with the best score for the second part of the modeling 
process: peptide extension. The central anchor residue, i.e. Arginine, was extended both 
in Nt and Ct directions by adding one residue at a time to match the sequence of the 
RNAP2 CTD peptide. In total 5000 models were generated for both PADI2 and PADI3 
bound to RNAP2 CTD peptide bearing R1810 residue and ranked according to Rosetta 
score (Fay et al., 2011). 
 
The analysis of sequence conservation was done as follow. The sequences of PADI1 
(UniProt ID: Q9ULC6), PADI2 (UniProt ID: Q9Y2J8), PADI3 (UniProt ID: 
W9ULW8), PADI4 (UniProt ID: Q9UM07) and PADI6 (UniProt ID: Q6TGC4) were 
aligned using ClustalW (Thompson et al., 1994).  From the multiple sequence 
alignment, a conservation score, ranging from 0 to 10, was computed for each residue 
using JalView (Waterhouse et al., 2009; Livingstone et al., 1993). 
 
QUANTIFICATION AND STATISTICAL ANALYSIS  
For super-resolution image analysis in Figure1D and Figure S2H, Pearson correlation 
was calculated for the fluorescent signal of the two channels of interest for each 
individual stack. Statistical analysis (two-tailed Student’s t-test) for the average z-stack 
Pearson´s correlation of each individual cell. For all experiments of RT-qPCR, ChIP-
qPCR and cell proliferation, a Two-tailed unpaired Student's t-test was used to 
determine statistical significance between the groups. Plots and indicated statistical 
analysis were done with the use of Prism (GraphPad Prism 6.0 for MacOS), unless 
otherwise stated. Correction between biological replicated of RNA and ChIP-
sequencing was calculated by Spearman´s correlation (R2). For all other experiments, 
significance between groups calculated by Wilcoxon-Mann-Whitney test. If exact p-
value are not shown or indicated in legend then p-values are represented in all figures as 
follows: *, p-value ≤ 0.05; **, p-value ≤ 0.01; ***, p-value ≤ 0.001; º, p-value > 0.05.   
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DATA AND SOFTWARE AVAILABILITY   
All high throughput sequencing data performed and used in this study have been 
deposited at GEO with accession code GSE105795.  
 
 
Supplementary Figure, Table and Movie Legends.  
 
Figure S1 (Related to Figure 1). Specificity of the anti-Cit1810 RNAP2 antibody 
(A) T47D cells extracts immunoprecipitated with pan-citrulline antibody and analyzed 
by western blot using antibodies against total-RNAP2, S5 and S2 phosphorylated forms 
of RNAP2. The dotted line indicates a separate gel (see methods) and lines on the left 
mark the migration of the 250 kDa size marker. (B) Dot blot showing the specificity of 
α−Cit1810, performed with 1, 0.2 and 0.04 µg of mentioned RNAP2-CTD peptides 
encompassing R1810 with specific post-translational modifications. Only the peptide 
bearing the Cit1810 modification were specifically recognized by α-Cit1810. (C) The 
specificity of α-Cit1810 was also confirmed by the peptide competition assay. α-
Cit1810 was incubated with 2µg of each of the indicated peptides for 30 minutes at 4ºC 
prior to probing the membrane with the Cit1810 peptide. (D) Duplicated western blot of 
T47D nuclear extract with α-Cit1810 run on Left: 3-8% SDS PAGE and Middle: 4-12% 
SDS PAGE, Right: Ponceau S staining of the 4-12% SDS PAGE gel. Line on the side 
mark the migration of the protein size marker. (E) Titration of the concentration of 
α−amanitin needed to deplete endogenous RNAP2 in T47D cells. Cells were incubated 
with increasing concentrations of α−amanitin (0, 2, 4 and 6µg/ml; lanes 1 to 4) for 12 
hours before preparing nuclear extracts. The extracts were probed in western blot with 
an antibody against total RNAP2; Tubulin was used as loading control. (F) Western blot 
of extracts from T47D cells depleted of endogenous RNAP2 by preincubation with 
6µg/ml α−amanitin, and transfected with empty vector (-) or with expression vectors for 
WTr or the R1810Ar mutant HA-tagged recombinant RNAP2 carrying an additional 
mutation that makes the enzyme resistant to α−amanitin (see Method). The western 
blots were probed with antibodies against the HA tag or total-RNAP2; Tubulin and 
GAPDH were used as loading control. (G) Immunofluorescence images of T47D cells 
using α−HA (green) and α−RNAP2 (red), depleted of endogenous RNAP2 by 
preincubation with 6µg/ml α−amanitin, and transfected with either expression vectors 
for (Left) WTr or the (Right) R1810Ar mutant HA-tagged recombinant RNAP2.  
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Figure S2 (Related to Figure 2). PADI2 interacts with CTD-R1810 in vivo and in 
vitro. (A) Western blot of extracts from T47D cells transfected with siRNA control 
(siCTRL) or siRNA against PADI3 (siPADI3) and probed with the indicated antibodies. 
(B) Immunofluorescence image of T47D cells transfected with siCTRL (upper panel) or 
siPADI2 (lower panel) using α−PADI2 (red) and α−Cit1810(green) along with DAPI. 
(C) Western blot of extracts from MCF7 cells transfected with siCTRL or siPADI2 and 
probed with the indicated antibodies. (D) Western blot of extracts from MCF7 cells 
transfected with siRNA CTRL or siPADI4 and probed with the indicated antibodies. 
The total intensity of PADI4 and PADI2 band quantitated by Image J after PADI4 
depletion and indicated underneath (siCTRL set to 1) (E-F) Immunoprecipitation of (E) 
T47D (F) MCF7 extracts with an α-total-RNAP2 or with non-immune rabbit IgG 
followed by western blot with the indicated antibodies. (G) Immunoprecipitation of 
T47D extracts with α-PADI2 or non-immune rabbit IgG probed with indicated 
antibodies. (H) Fractionation of T47D cells extract using a Superdex 200 gel filtration 
column and analysis of the eluted fractions by western blotted with the indicated 
antibodies. (I) Left: Representative super-resolution immunofluorescence images of 
T47D cells using triple labeling with α-Cit1810 (red) in combination with α-S2P-
RNAP2 (green) and α-PADI2 (blue). Plot representing the mean Pearson correlation 
coefficient of several individual cells (n=16), for PADI2 with Cit1810 (purple), for S2P-
RNAP2 with Cit1810 (yellow) and for PADI2 with S2P-RNAP2 (cyan). Right: Person 
correlation coefficient presented a value of mean ± SEM. Note Cit1810-RNAP2 showed 
co-localization with PADI2 as well as with S2P-RNAP2 (shown as white in the merged 
image). 
Figure S3 (Related to Figure 3). PADI2 depletion affects genes involved in cell 
cycle progression. (A) Changes in PADI2, PADI3 and HMOX1 mRNA quantified by 
RT-qPCR in T47D cells transfected with siPADI2 (orange bars) or siPADI3 (grey bars). 
mRNA levels were normalized to a GAPDH mRNA expression level, which was not 
affected in these experimental conditions, and are presented as a ratio to levels in cells 
transfected siCTRL. Values are the mean ± SEM of at least three biological replicates as 
in other plots in the figure. (B) Volcano plot showing indicated gene biotypes of 
differentially expressed genes determined from polyA-RNA sequencing as shown in 
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Figure 3A. The X-axis represents log2 expression fold changes (FC) and the Y-axis 
represents the adjusted p-values (as -log10). (C) Gene set enrichment analysis (GSEA) 
for biological processes and molecular functions. Seven representative processes are 
presented. The X-axis shows the -log10 transformed p-values. GO, Gene Ontology. (D) 
The mRNA-seq data validated by RT-qPCR for indicated genes. Y-axis shows the fold 
change over siCTRL, orange color indicates data from duplicate RNA-seq and green 
color from RT-qPCR (mean ± SEM from at least three experiments). (E) Knockdown of 
CARM1 mRNA (>80% depletion relative to siCTRL) did not significantly affect PADI-
dependent gene transcripts. Data are shown as fold change over siCTRL and represent 
mean ± SEM. Extracts from siCTRLand siCARM1 transfected cells were probed with 
indicated antibodies to estimate CARM1 depletion (>80%). (F) Knockdown of PRMT5 
mRNA (>80% relative to siCTRL mRNA) did not significantly affect PADI-dependent 
gene transcripts. Extracts from siCTRL and siPRMT5 transfected cells were probed with 
indicated antibodies to estimate PRMT5 depletion (>90%). (G) Browser snapshots of 
control GSTT2 (related to Figure 3D) gene in T47D cells showing chromatin associated 
RNAs sequencing profile (orange) and mRNA sequencing profiles after PADI2 
knockdown (blue) and expressing WTr and R1810r mutant form of RNAP2 (Green). 
Scale is indicated on the top of the gene. (H) Left: Cell cycle profile of T47D cells 
transfected with siCTRL (black) and siPADI2 (orange) obtained by propidium iodide 
labeling followed by fluorescence-activated cell sorting (FACS) analysis. Right: 
Histogram showing the percentage of cells during cell cycle phases. Data presented as 
mean ± SEM from three biological replicates. p-value was calculated by student's t test, 
* p-value < 0.05, ** p-value < 0.001. (I) Left: Venn diagram showing the set of genes 
related to cell cycle (GO:0007049 (n= 315, Out of them 282 genes expressed in T47D 
cells) down regulated in T47D cells after PADI2 depletion (PADI2 dependent) versus 
PADI2 independent gene (see Table S2). Right: Box plot showing log2 fold change (si 
PADI2/si CTRL) for PADI2 dependent and independent cell cycle genes. Each box in 
the panel represents the interquartile range; Whisker extends the box to the highest and 
lowest values, horizontal lines indicate the median value. Dependent genes showed 
significant lower mRNA levels than independent genes (***p-value < 0.0001, 
calculated by Wilcoxon-Mann-Whitney test). (J) Venn diagram representing the set of 
cell cycle genes dependent on PADI2 and R1810 RNAP2-CTD (see Table S2). (K) 
Word cloud of all the PADI2 dependent genes represented in Figure S3I; Size of genes 
indicates an extent of down-regulation after PADI2 depletion as measured by the log2 
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fold change siPADI2/siCTRL. 
Figure S4 (Related to Figure 4). RNAP2 and PADI2 co-localize on highly 
transcribed genes. (A) Browser snapshots representing the PADI2 and RNAP2 
occupancy on highly transcribed genes SERPINA6 and HMGN1 versus lowly expressed 
genes (GSTT2 and LRRC39. A scale is shown on the top for each gene. Y-axis: reads 
per million (RPM). (B) PADI2 occupancy monitored along the gene bodies by PADI2 
ChIP assay in T47D cells transfected with siPADI2 or siCTRL followed by qPCR along 
the gene bodies of two highly transcribed genes (SERPINA6, c-MYC) and a low 
transcribed gene (GSTT2). Non-immune IgG was used as negative control. Y-axis: 
PADI2 enrichment over input samples. Data represented as mean ± SEM from at least 
three biological replicates as in other plots of the figure. Top: basic gene structure and 
scale with the positions of the amplicons. (C) PADI2 ChIP-seq normalized reads in a 
window from 3kb upstream of TSS to 3kb downstream of TTS on genes down regulated 
and non-regulated genes after PADI2 depletion in mRNA-sequencing (left) and 
ChrRNA-sequencing (right). Down regulated genes showed significantly higher PADI2 
recruitment both from mRNA-seq and ChrRNA-seq as indicated, p-value was 
calculated by Wilcoxon-Mann-Whitney test. Box represents the interquartile range; 
Whisker extends the box to the highest and lowest values. A line across each box 
indicate the median value. (D) RNAP2 ChIP followed by PADI2 re-ChIP assay 
performed in T47D cells to examine co-localization on promoter regions (A primer) and 
exons (B or C primers) of two highly transcribed genes (SERPINA6, c-MYC) and a low 
transcribed gene (GSTT2).  
Figure S5 (Related to Figure 5). PADI2 directed citrullination of R1810 regulates 
pausing of highly transcribed genes. (A-B) RNAP2 ChIP qPCR performed in T47D 
cells after PADI2 depletion with an antibody to RNAP2 or in cells expressing only the 
HA-tagged wild-type (WTr) or R1810Ar mutant of RNAP2 with the HA antibody. (A) 
Promoter region of PADI2 and R1810 dependent genes (SERPINA6, c-MYC, HMGN1) 
(B) Intragenic regions of PADI2 and R1810 dependent genes. Primers for intragenic 
regions were SERPINA6-C, c-MYC-B and HMGN1-B (Table S4). Non-immune IgG 
was used as negative control. Y-axis: fold change over the input samples. (C) S5P and 
S2P RNAP2 occupancy was monitored along the gene bodies by performing ChIP assay 
in T47D cells transfected with siCTRL or siPADI2 (black or yellow), or T47D cells 
expressing only WTr or the R1810Ar mutant of RNAP2 (grey or orange) followed by 
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quantitative PCRs along the gene bodies. Y-axis: relative enrichment normalized to 
total RNAP2; values are means ± SEM. Top:  For each gene, the basic gene structure 
and the position of the amplicons are indicated. (D) Higher pausing index in the cell 
expressing R1810Ar mutant as compared to WTr form of RNAP2 calculated for shared 
939 genes down regulated after PADI2 depletion (2,186) and R1810 dependent (1392 
genes found significantly down regulated by considering FC < 1/1.5 and p-value < 0.01, 
after expressing R1810Ar mutant as compared to WTr   RNAP2) in T47D. (E-F) Box 
plot of the pausing index of (E) top 25% down-regulated and up-regulated genes after 
PADI2 depletion from mRNA-seq (left) and ChrRNA-seq (right). (F) Down regulated 
(n=1392) and up regulated (n=1372) genes obtained from replicate mRNA-seq 
performed in T47D cells expressing R1810Ar mutant as compared to WTr form of 
RNAP2. p-value was calculated by Wilcoxon-Mann-Whitney test. Each box represents 
the interquartile range; Whisker extends the box to the highest and lowest values. A line 
across each box indicate the median value.   
 
Figure S6 (Related to Figure 7). PADIs conservation homology analysis. Ribbon 
representation of top ranking structural model of PADI2 bound to CTD-R1810 peptide. 
Residues colored according to its conservation among human PADIs (PADI1, PADI2, 
PADI3, PADI4 and PADI6) as shown in the conservation scale. Inset: Close up of the 
peptide binding side and selected residues shown in stick representation. R1810 shown 
as reference in ball and stick representation both in full size and close up. The partial 
alignments show each selected residue (LEU642 and ARG580 residues, non-conserved 
unique to PADI2, in orange color and ASP374 and SER401, residues not unique to 
PADI2, in blue color) and flanking regions with a histogram underneath showing the 
conservation among PADIs as indicated in scale.  
 
Figure S7 (Related to Figure 7). Identification of PADI2 unique residues for CTD-
R1810 specificity. (A) Box plot showing the distribution of energies decomposed (Y-
axis) for each interface residue (X-axis) among the top 200 structural models of PADI2-
CTD-R1810 peptide (Table S3). Residues are sorted by increasing conservation from 
left to right in the X-axis and labelled as follow: three letters residue type, residue 
number and conservation (between 0 to 10). box represents the interquartile range; 
Whisker extends the box to the highest and lowest values. A line across each box 
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indicate the median value. (B) Coomassie blue staining of SDS-PAGE with 
recombinant HIS-tagged wild-type (WT), D374K, S401A, R580E and L642T PADI2 
proteins used for the citrullination assay. 
 
Table S1 (Related to Figure 3 and Figure S3).  GO Biological and molecular function 
analysis for differentially expressed after PADI2 knock down as shown in Figure 3A 
and Figure S5C. Significant (p< 0.05). 
Table S2 (Related to Figure 3 and Figure S3). List of cell cycle genes dependent and 
independent on R1810 RNAP2-CTD and PADI2 as indicated in Figure 3H and Figure 
S3J. 
Table S3 (Related to Figure 7). List of interface residues of PADI2-CTD-R1810 
peptide and binding energy. First and second column show the residue number and 
residue type respectively; third column indicates the sequence conservation among all 
PADIs family members. Last column lists the Rosetta total energy for the given residue 
amongst the top 200 structural models. 
Table S4 (Related to the STAR method). List of primers used for qPCRs.  
Movie S1 (Related to Figure 7). A movie showing a 360-degree rotation of the lowest 
energy structural model of PADI2-CTD-R1810 peptide complex. PADI2 is shown in 
cartoon and surface representation (green) and R1810 RNAP2-CTD peptide in ribbon 
(magenta); selected amino acid for mutation studies R580, L642 and D374 and S401 are 
shown in orange and blue respectively. 
Movie S2 (Related to Figure 7). A movie showing a 360-degree rotation of the lowest 
energy model of PADI3-CTD-R1810 peptide complex. PADI3 is shown in cartoon and 
surface representation (grey) and R1810 RNAP2-CTD peptide in ribbon (magenta). 
